Jennifer Michaelson - 17 Feb 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Development Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
17 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 17:52:34 UTC
Previous filing
29 Nov 2022
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +38,500 +73% $0.000000 91,531 17 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +77,000 $0.000000 77,000 17 Feb 2023 Common Stock 77,000 $11.34 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.